ストックスクリーナーアプリを入手
3.19
1.92%
0.06
Atea Pharmaceuticals Inc (AVIR) 最新ニュース
Atea Pharmaceuticals Faces Shareholder Revolt Over Director's Stock Sale, Strategic Decisions - StockTitan
Atea Pharmaceuticals engages Evercore to explore partnerships - MSN
Atea Pharmaceuticals, Inc. Engages Evercore to Identify Potential Opportunities to Enhance Shareholder Value, Including the Exploration of Strategic Partnerships Related to Its Phase 3-Ready Program for the Treatment of Hepatitis C Virus - Marketscreener.com
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships - GlobeNewswire
Atea Pharmaceuticals Taps Evercore to Explore Strategic Options for Phase 3 HCV Program - StockTitan
Charles Schwab Investment Management Inc. Acquires 50,794 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals director Franklin Berger sells $1.02 million in stock By Investing.com - Investing.com Australia
Atea Pharmaceuticals director Franklin Berger sells $1.02 million in stock - Investing.com
Fmr LLC Buys 182,174 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Atea Pharmaceuticals stock hits 52-week low at $2.88 By Investing.com - Investing.com Australia
Atea Pharmaceuticals stock hits 52-week low at $2.88 - Investing.com
Atea Pharmaceuticals announces results from Phase 2 regimen of bemnifosbuvir - Yahoo Finance
Atea Aims For Underserved HCV Niche With Combo Regimen - News & Insights
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study - Yahoo Finance
Atea reports high efficacy in Phase 2 HCV treatment study - Investing.com
Atea Pharmaceuticals Announces Positive Results from Phase - GlobeNewswire
Atea's HCV Drug Achieves 98% Cure Rate in Phase 2 Trial, Shows Breakthrough Promise - StockTitan
Atea plans Phase 3 study for hepatitis C drug after mid-stage results - Yahoo Finance
Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference - GlobeNewswire
Atea Pharmaceuticals CEO to Present at Evercore HealthCONx Conference | AVIR Stock News - StockTitan
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? - MSN
Island Pharmaceuticals Advances Dengue Clinical Trial - MSN
Atomo Diagnostics Plans Share Issuance to Boost Capital - MSN
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024 - GlobeNewswire
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024 - GlobeNewswire Inc.
FMR LLC Increases Stake in Atea Pharmaceuticals Inc - GuruFocus.com
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is BML Capital Management LLC's 3rd Largest Position - MarketBeat
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2024 Earnings Call Transcript - Insider Monkey
Atea Pharmaceuticals Advances in HCV Treatment Development - TipRanks
Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Atea Reports $31.2M Loss, Exits COVID Program Despite Strong HCV Pipeline Results | AVIR Stock News - StockTitan
Appian Cl A Sees RS Rating Improve To 72 - MSN
AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Thursday - MarketBeat
Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 - The Manila Times
Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024 - The Manila Times
Atea Pharmaceuticals to Present New Data Supporting the - GlobeNewswire
Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024 - StockTitan
SG Americas Securities LLC Increases Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Respiratory Syncytial Virus Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | GSK, MedImmune, ReViral, Pfizer, Sanofi, BioComo, Merck - The Globe and Mail
Morgan Stanley Upgrades Atea Pharmaceuticals (AVIR) - MSN
Atea Pharmaceuticals Leads The Charge In US Penny Stocks Spotlight - Simply Wall St
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Yahoo Finance
Dimensional Fund Advisors LP Buys 211,428 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
182,326 Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Purchased by Marshall Wace LLP - MarketBeat
Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Almitas Capital LLC Invests $4.27 Million in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):